Using genetic techniques to improve cancer treatment targeting KRAS mutations
Exploiting synthetic lethality to enhance KRAS inhibitor therapy of cancer
This study is looking at new ways to improve treatments for cancers with a specific KRAS mutation, like lung and colorectal cancer, by combining different therapies to help patients get better results.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11204766 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of therapies that target KRAS mutations, particularly the KRASG12C mutation found in various cancers like non-small cell lung cancer and colorectal cancer. The approach involves exploiting synthetic lethality, which means identifying and targeting vulnerabilities in cancer cells that have specific genetic mutations. By combining KRAS inhibitors with other treatments, the goal is to overcome resistance that often limits the success of current therapies. Patients may be involved in trials that test these new combinations to see if they can achieve better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cancers harboring KRASG12C mutations, such as non-small cell lung cancer or colorectal cancer.
Not a fit: Patients without KRAS mutations or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with KRAS-mutated cancers, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting KRAS mutations, but this specific approach of combining therapies to overcome resistance is still being explored.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Neel, Benjamin G. — New York University School of Medicine
- Study coordinator: Neel, Benjamin G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.